Clinical Trials · NCT02736448
177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors
- Phase
- Phase 2
- Recruitment status
- Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
- Enrollment
- 35
- Start date
- May 2016
- Locations
- 1 site, Italy
- Primary endpoint
- Progression free survival